- Home
- BY vs VIR Comparison
BY vs VIR Comparison
Compare BY & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BY
- VIR
- Stock Information
- Founded
- BY 1914
- VIR 2016
- Country
- BY United States
- VIR United States
- Employees
- BY N/A
- VIR N/A
- Industry
- BY Major Banks
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- BY Finance
- VIR Health Care
- Exchange
- BY Nasdaq
- VIR Nasdaq
- Market Cap
- BY 1.2B
- VIR 1.4B
- IPO Year
- BY 2017
- VIR 2019
- Fundamental
- Price
- BY $28.93
- VIR $9.57
- Analyst Decision
- BY Hold
- VIR Buy
- Analyst Count
- BY 3
- VIR 6
- Target Price
- BY $33.67
- VIR $34.83
- AVG Volume (30 Days)
- BY 116.4K
- VIR 1.2M
- Earning Date
- BY 01-23-2025
- VIR 02-26-2025
- Dividend Yield
- BY 1.38%
- VIR N/A
- EPS Growth
- BY 3.00
- VIR N/A
- EPS
- BY 2.75
- VIR N/A
- Revenue
- BY $379,856,000.00
- VIR $78,618,000.00
- Revenue This Year
- BY N/A
- VIR N/A
- Revenue Next Year
- BY $5.17
- VIR N/A
- P/E Ratio
- BY $10.51
- VIR N/A
- Revenue Growth
- BY 7.52
- VIR N/A
- 52 Week Low
- BY $19.70
- VIR $6.56
- 52 Week High
- BY $32.89
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- BY 45.27
- VIR 48.60
- Support Level
- BY $29.33
- VIR $9.54
- Resistance Level
- BY $30.03
- VIR $9.97
- Average True Range (ATR)
- BY 0.66
- VIR 0.55
- MACD
- BY -0.04
- VIR -0.08
- Stochastic Oscillator
- BY 24.24
- VIR 39.89
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium-sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to our customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.